Stock Financial Ratios, Dividends, Split History

TPRE / Third Point Reinsurance Ltd. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)1,399.48
Enterprise Value ($M)1,396.69
Book Value / Share16.03
Price / Book0.84
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Preferred Stock Shares Outstanding 0
Weighted Average Number Of Shares Outstanding Basic 102,264,094
Weighted Average Number Of Diluted Shares Outstanding 105,227,038
Common Shares Outstanding 103,282,427
Common Stock Shares Outstanding 103,282,427
Scoring Models
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.17
Return on Assets (ROA)0.07
Return on Equity (ROE)0.20
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Net Income281.77
Cash Flow Statement (mra) ($M)
Cash From Operations-78.54
Cash from Investing23.05
Cash from Financing23.05
Identifiers and Descriptors
Central Index Key (CIK)1576018
Related CUSIPS
0G8827U10 G8827U900 G8827U950

Split History

Stock splits are used by Third Point Reinsurance Ltd. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

Tracking Dan Loeb's Third Point Portfolio - Q1 2018 Update

2018-05-22 seekingalpha
Dan Loeb's 13F portfolio value decreased from $13.86B to $13.32B this quarter. The number of positions decreased from 44 to 40. (991-1)

Third Point Reinsurance's (TPRE) CEO Rob Bredahl on Q1 2018 Results - Earnings Call Transcript

2018-05-13 seekingalpha
Greetings, and welcome to the Third Point Reinsurance First Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. (12-1)

Third Point's Dan Loeb to increase bets against the stock market

2018-05-13 cnbc
Following a quarter in which his two flagship funds posted losses, the head of Third Point said he is increasing short positions that proved to be profitable during an otherwise rough first quarter. (0-1)

Loeb's Third Point Boosts Short Wagers on Market Disruption - Bloomberg

2018-05-10 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Check These 2 Insurance Stocks Poised for Q1 Earnings Beat

2018-05-04 zacks
The first-quarter earnings season has crossed its midpoint with more than 68% of the S&P 500 index members having reported quarterly results. Per the Earnings Outlook, the beat ratio is impressive with 78.4% of the participants surpassing bottom-line estimates and 75.8%, exceeding the top-line mark. Per the Earnings Outlook, earnings growth is estimated to be in double-digit in 13 of the 16 Zacks sectors including the Finance. (2-1)

CUSIP: G8827U100